News
Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...
Hosted on MSN5mon
Why Novo Nordisk surged 14% on new weight-loss drug results - MSNShares of Danish pharmaceutical giant Novo Nordisk surged close to 14% on Friday after the company announced positive results from early-stage trials for its once-weekly obesity treatment, amycretin.
Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.
The stock of Novo Nordisk (NYSE: NVO) has been a hot buy over the past few years (up 270% in three years), largely due to the success of its diabetes and weight loss drugs.
Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.
More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...
The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...
Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli Lilly began marketing its rival product Mounjaro in the world's most ...
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
Novo Nordisk A/S has a successor waiting in the wings for the generation of weight-loss shots it pioneered: a pill that helps people shed pounds without the drawbacks of an injection.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results